The functional role of long non-coding RNA in human carcinomas

Ewan A Gibb1*, Carolyn J Brown1,2 and Wan L Lam1,3

Abstract
Long non-coding RNAs (lncRNAs) are emerging as new players in the cancer paradigm demonstrating potential roles in both oncogenic and tumor suppressive pathways. These novel genes are frequently aberrantly expressed in a variety of human cancers, however the biological functions of the vast majority remain unknown. Recently, evidence has begun to accumulate describing the molecular mechanisms by which these RNA species function, providing insight into the functional roles they may play in tumorigenesis. In this review, we highlight the emerging functional role of lncRNAs in human cancer.

Introduction
One of modern biology’s great surprises was the discovery that the human genome encodes only ~20,000 protein-coding genes, representing <2% of the total genome sequence [1,2]. However, with the advent of tiling resolution genomic microarrays and whole genome and transcriptome sequencing technologies it was determined that at least 90% of the genome is actively transcribed [3,4]. The human transcriptome was found to be more complex than a collection of protein-coding genes and their splice variants; showing extensive antisense, overlapping and non-coding RNA (ncRNA) expression [5-10]. Although initially argued to be spurious transcriptional noise, recent evidence suggests that the proverbial “dark matter” of the genome may play a major biological role in cellular development and metabolism [11-17]. One such player, the newly discovered long non-coding RNA (lncRNA) genes, demonstrate developmental and tissue specific expression patterns, and aberrant regulation in a variety of diseases, including cancer [18-27].

NcRNAs are loosely grouped into two major classes based on transcript size; small ncRNAs and IncRNAs (Table 1) [28-30]. Small ncRNAs are represented by a broad range of known and newly discovered RNA species, with many being associated with 5' or 3' regions of genes [4,31,32]. This class includes the well-documented miRNAs, RNAs ~22 nucleotides (nt) long involved in the specific regulation of both protein-coding, and putatively non-coding genes, by post-transcriptional silencing or infrequently by activation [33-35]. miRNAs serve as major regulators of gene expression and as intricate components of the cellular gene expression network [33-38]. Another newly described subclass are the transcription initiation RNAs (tiRNAs), which are the smallest functional RNAs at only 18 nt in length [39,40]. While a number of small ncRNAs classes, including miRNAs, have established roles in tumorigenesis, an intriguing association between the aberrant expression of ncRNA satellite repeats and cancer has been recently demonstrated [41-46].

In contrast to miRNAs, IncRNAs, the focus of this article, are mRNA-like transcripts ranging in length from 200 nt to ~100 kilobases (kb) lacking significant open reading frames. Many identified IncRNAs are transcribed by RNA polymerase II (RNA pol II) and are polyadenylated, but this is not a fast rule [47,48]. There are examples of IncRNAs, such as the antisense asOct4-pg5 or the brain-associated BC200, which are functional, but not polyadenylated [49-51]. Generally, IncRNA expression levels appear to be lower than protein-coding genes [52-55], and some IncRNAs are preferentially expressed in specific tissues [21]. However, recent findings have suggested novel IncRNAs may contribute a significant portion of the aforementioned ‘dark matter’ of the human transcriptome [56,57]. In an exciting report by Kapranov et al., it was revealed the bulk of the relative mass of RNA in a human cell, exclusive of the ribosomal and mitochondrial RNA, is represented by non-coding transcripts with no known function [57].
Like miRNAs and protein-coding genes, some transcriptionally active lncRNA genes display histone H3K4 trimethylation at their 5'-end and histone H3K36 trimethylation in the body of the gene [8,58,59]. The small number of characterized human lncRNAs have been associated with a spectrum of biological processes, for example, epigenetics, alternative splicing, nuclear import, as structural components, as precursors to small RNAs and even as regulators of mRNA decay [4,60-70]. Furthermore, accumulating reports of misregulated lncRNA expression across numerous cancer types suggest that aberrant lncRNA expression may be a major contributor to tumorigenesis [71]. This surge in publications reflects the increasing attention to this subject (Figure 1) and a number of useful lncRNA databases have been created (Table 2). In this review we highlight the emerging functional role of aberrant lncRNA expression, including transcribed ultraconserved regions (T-UCRs), within human carcinomas.

| Type                              | Subclasses                                      | Symbol         | References |
|-----------------------------------|-------------------------------------------------|----------------|------------|
| **Transfer RNAs**                | tRNAs                                           | [222]          |            |
| **MicroRNAs**                    | miRNAs                                          | [33,34]        |            |
| **Ribosomal 5S and 5.8S RNAs**   | rRNAs                                           | [223,224]      |            |
| **Piwi interacting RNAs**        | piRNAs                                          | [38,225]       |            |
| **Tiny transcription initiation RNAs** | tRNA                                             | [39,40]        |            |
| **Small interfering RNAs**       | siRNA                                           | [32]           |            |
| **Promoter-associated short RNAs** | PASRs                                             | [144,149]     |            |
| **Termini-associated short RNAs** | TASRs                                             | [144,149]     |            |
| **Antisense termini associated short RNAs** | aTASRs                                         | [226]          |            |
| **Small nuclear RNAs**           | snoRNAs                                         | [227,228]      |            |
| **Transcription start site antisense RNAs** | TSSa-RNAs                                       | [229]          |            |
| **Small nuclear RNAs**           | snRNAs                                          | [230]          |            |
| **Retrotransposon-derived RNAs** | RE-RNAs                                         | [231,232]      |            |
| **3'UTR-derived RNAs**           | uARNA                                           | [145]          |            |
| **x-ncRNA**                      | x-ncRNA                                         | [233]          |            |
| **Human Y RNA**                  | hY RNA                                          | [234]          |            |
| **Unusually small RNAs**         | usRNAs                                          | [235]          |            |
| **Small NF90-associated RNAs**   | smaRS                                           | [236,237]      |            |
| **Vault RNAs**                   | vtRNAs                                          | [238]          |            |
| **Ribosomal 18S and 28S RNAs**   | rRNAs                                           | [223,224]      |            |
| **Long or large intergenic ncRNAs** | lincRNAs                                        | [8,58]         |            |
| **Transcribed ultraconserved regions** | T-UCRs                                         | [85]           |            |
| **Pseudogenes**                  | none                                            | [239,240]      |            |
| **GAA-repeat containing RNAs**   | GRC-RNAs                                        | [241]          |            |
| **Long intronic ncRNAs**         | none                                            | [242,243]      |            |
| **Antisense RNAs**               | aRNAs                                           | [244]          |            |
| **Promoter-associated long RNAs** | PALRs                                            | [144,149]     |            |
| **Promoter upstream transcrits**  | PROMPTs                                         | [245]          |            |
| **Stable excised intron RNAs**   | none                                            | [56]           |            |
| **Long stress-induced non-coding transcripts** | LSINCTs                                         | [25]           |            |

![Figure 1](http://www.molecular-cancer.com/content/10/1/38)  
**Figure 1 Publications describing cancer-associated ncRNAs**  
Entries are based on a National Library of Medicine Pubmed search using the terms “ncRNA” or “non-coding RNA” or “noncoding RNA” or non-protein-coding RNA” with cancer and annual (Jan.1-Dec.31) date limitations.
Background on Long Non-Coding RNA

Nomenclature and Classification of LncRNA

The definition ‘non-coding RNA’ is typically used to describe transcripts where sequence analysis has failed to identify an open reading frame. However, one should exercise caution when exploring putative non-coding transcripts, as there are cases where ‘non-coding’ transcripts were found to encode short, functional peptides [72]. Currently, a universal classification scheme to define lncRNAs does not exist and therefore there are numerous synonyms describing the same type of transcripts. Terms such as large non-coding RNA, mRNA-like long RNA, and intergenic RNA all define cellular RNAs, exclusive of rRNAs, greater than 200 nt in length and having no obvious protein-coding capacity [62]. Consequently, this has led to confusion in the literature as to exactly which transcripts should constitute a lncRNA. For example, one subclass of lncRNAs is called large or long intergenic ncRNAs (lincRNAs). These lncRNAs are exclusively intergenic and are marked by a chromatin signature indicative of transcription [8,58]. To further compound classification confusion, RNA species that are bifunctional preclude categorization into either group of protein-coding or ncRNAs as their transcripts function both at the RNA and protein levels [73].

Discovery of LncRNAs

The earliest reports describing lncRNA predated the discovery of miRNAs, although the term ‘lncRNA’ had not been coined at the time (Figure 2). One of the first lncRNA genes reported was the imprinted H19 gene, which was quickly followed by the discovery of the silencing X-inactive-specific transcript (XIST) lncRNA gene, which plays a critical function in X-chromosome inactivation [74,75]. However, the discovery of the first miRNA lin-14 dramatically redirected the focus of ncRNA research from long ncRNAs to miRNAs [76]. Moreover, during this time the discovery of miRNAs revealed RNA could regulate gene expression and later that entire gene networks could be affected by ncRNA expression and within the last decade miRNAs were discovered to be associated with cancer (Figure 2) [76-79]. At the time of this writing there are approximately 1049 human miRNAs described in miRBase V16 [80,81] with the potential of affecting the expression of approximately 60% of protein-coding genes [82,83]. Conversely,

| Database Name     | Website                           | Reference |
|-------------------|-----------------------------------|-----------|
| ncRNAimprint      | http://maqueen.sysu.edu.cn/ncRNAimprint/ | [246]     |
| ncRNAdb           | http://research.imb.uq.edu.au/ncadb/ | [247]     |
| Functional RNAdb  | http://www.ncrna.org/frnadb/       | [248]     |
| NONCODE           | http://www.noncode.org/            | [249]     |
| lncRNA db         | http://longnoncodingrna.com/       | [250]     |
| Rfam              | http://rfam.sanger.ac.uk/          | [251]     |
| NRED              | http://jsm-research.imb.uq.edu.au/nred/cgi-bin/ncreadb.pl | [252]     |
| Ncode (Invitrogen) | http://escience.invitrogen.com/ncRNA/ | N/A       |
| NcRNA Database    | http://biobases.ibch.poznan.pl/ncRNA/ | [253]     |
| T-UCRs            | http://users.soe.ucsc.edu/~jill/ultra.html | [202]     |
| NPInter           | http://www.bioinfo.org.cn/NPInter/  | [254]     |

Figure 2 Timeline of cancer-associated ncRNA discoveries relative to transcriptome analysis technologies (not drawn to scale)
the variety and dynamics of lncRNA expression was not to be fully appreciated until the introduction of whole transcriptome sequencing. With the advent of the FANTOM and ENCODE transcript mapping projects, it was revealed that the mammalian genome is extensively transcribed, although a large portion of this represented non-coding sequences [3,84]. Coupled with the novel functional annotation of a few lncRNAs, this discovery promoted research focusing on lncRNA discovery and characterization. Recent reports have described new lncRNA classes such as lincRNAs and T-UCRs [8,58,85]. Current estimates of the lncRNA gene content in the human genome ranges from ~7000 - 23,000 unique lncRNAs, implying this class of ncRNA will represent an enormous, yet undiscovered, component of normal cellular networks that may be disrupted in cancer biology [62].

Emerging Role of Long Non-Coding RNA in Tumorigenesis

A role for differential lncRNA expression in cancer had been suspected for many years, however, lacked strong supporting evidence [86]. With advancements in cancer transcriptome profiling and accumulating evidence supporting lncRNA function, a number of differentially expressed lncRNAs have been associated with cancer (Table 3). LncRNAs have been implicated to regulate a range of biological functions and the disruption of some of these functions, such as genomic imprinting and transcriptional regulation, plays a critical role in cancer development. Here we describe some of the better characterized lncRNAs that have been associated with cancer biology.

Imprinted lncRNA genes

Imprinting is a process whereby the copy of a gene inherited from one parent is epigenetically silenced [87,88]. Intriguingly, imprinted regions often include multiple maternal and paternally expressed genes with a high frequency of ncRNA genes. The imprinted ncRNA genes are implicated in the imprinting of the region by a variety of mechanisms including enhancer competition and chromatin remodeling [89]. A key feature of cancer is the loss of this imprinting resulting in altered gene expression [90,91]. Two of the best known imprinted genes are in fact lncRNAs.

| LncRNA   | Size (nt) | Cytoband | Cancer types                                                                 | References                                                                 |
|----------|-----------|----------|-------------------------------------------------------------------------------|----------------------------------------------------------------------------|
| HOTAIR   | 2158      | 12q13.13 | Breast                                                                        | [18,68]                                                                    |
| MALAT1/a | 7.5 kb    | 11q13.1  | Breast, lung, uterus, pancreas, colon, prostate, liver, cervix, neuroblastoma, osteosarcoma | [135,137-139,152,255,256]                                                  |
| HULC     | 500 nt    | 6p24.3   | Liver, hepatic colorectal metastasis                                          | [170,171]                                                                  |
| BC200    | 200 nt    | 2p21     | Breast, cervix, esophagus, lung, ovary, parotid, tongue                      | [50,51]                                                                   |
| H19      | 2.3 kb    | 11p15.5  | Bladder, lung, liver, breast, endometrial, cervix, esophagus, ovary, prostate, choriocarcinoma, colorectal | [74,92,95,97,102,103,257-264]                                               |
| BIC/MIRHG155/ MIRHG2 | 1.6 kb | 2q11.2   | B-cell lymphoma                                                              | [153]                                                                     |
| PRNCR1   | 13 kb     | 8q24.2   | Prostate                                                                      | [187]                                                                     |
| LOC285194| 2105 nt   | 3q13.31  | Osteosarcoma                                                                  | [265]                                                                     |
| PCGEM1   | 1643 nt   | 2q32.2   | Prostate                                                                      | [188,266,267]                                                              |
| UCA1/CUDR| 1.4 kb, 2.2 kb, 2.7 kb | 19p13.12 | Bladder, colon, cervix, lung, thyroid, liver, breast, esophagus, stomach | [268-270]                                                                 |
| DD3/PCA3 | ~1.9 kb   | 9q21.22  | Prostate                                                                      | [189,190]                                                                 |
| anti-NOS2A| ~0.6 kb, 2 kb, 4 kb | 17q23.2 | Brain¹                                                                        | [271]                                                                     |
| uc.73A   | 201 nt    | 2q22.3   | Colon                                                                         | [200]                                                                     |
| TUC338 (encodes uc.338) | 590 nt | 12q13.13 | Liver                                                                          | [203]                                                                     |
| ANRIL/p15AS/ CDK2BA5 | 34.8 kb & splice variants | 9p21.3 | Prostate, leukemia                                                            | [175,176,183,272]                                                         |
| MEG3     | 1.6 kb & splicing isoforms | 14q32.2 | Brain (downregulated)                                                         | [156-158,162]                                                             |
| GASS/SNHG2| Multiple isoforms | 1q25.1 | Breast (downregulated)                                                        | [273]                                                                     |
| SRA-1/SRA (bifunctional) | 1965 nt | 5q31.3   | Breast, uterus, ovary (hormone responsive tissue)                            | [274,275]                                                                 |
| PTENP1   | ~3.9 kb   | 9p13.3   | Prostate                                                                      | [173,174]                                                                 |
| ncNAN    | 2186 nt, 2087 nt | 17q25.1 | Bladder, neuroblastoma                                                       | [276,277]                                                                 |

¹ Cell lines.
its reciprocally imprinted protein-coding neighbor the Insulin-Like Growth Factor 2 or IGF2 gene at 11p15.5 were among the first genes, non-coding or otherwise, found to demonstrate genomic imprinting [74,92]. The expression of H19 is high during vertebrate embryo development, but is downregulated in most tissues shortly after birth with the exception of skeletal tissue and cartilage [20,93,94]. Loss of imprinting and subsequent strong gene expression has been well-documented in human cancers. Likewise, loss of imprinting at the H19 locus resulted in high H19 expression in cancers of the esophagus, colon, liver, bladder and with hepatic metastases [95-97].

H19 has been implicated as having both oncogenic and tumor suppression properties in cancer. H19 is upregulated in a number of human cancers, including hepatocellular, bladder and breast carcinomas, suggesting an oncogenic function for this IncRNA [97-99]. In colon cancer H19 was shown to be directly activated by the oncogenic transcription factor c-Myc, suggesting H19 may be an intermediate functionary between c-Myc and downstream gene expression [98]. Conversely, the tumor suppressor gene and transcriptional activator p53 has been shown to down-regulate H19 expression [100,101]. H19 transcripts also serve as a precursor for miR-675, a miRNA involved in the regulation of developmental genes [102]. miR-675 is processed from the first exon of H19 and functionally downregulates the tumor suppressor gene retinoblastoma (RB1) in human colorectal cancer, further implying an oncogenic role for H19 [103].

There is evidence suggesting H19 may also play a role in tumor suppression [104,105]. Using a mouse model for colorectal cancer, it was shown that mice lacking H19 manifested an increased polyp count compared to wild-type [106]. Secondly, a mouse teratocarcinoma model demonstrated larger tumor growth when the embryo lacked H19, and finally in a hepatocarcinoma model, mice developed cancer much earlier when H19 was absent [107]. The discrepancy as to whether H19 has oncogenic or tumor suppressive potential may be due in part to the bifunctional nature of the IncRNA or may be context dependent. In either case, the precise functional and biological role of H19 remains to be determined.

**XIST - X-inactive-specific transcript** The 17 kb IncRNA XIST is arguably an archetype for the study of functional IncRNAs in mammalian cells, having been studied for nearly two decades. In female cells, the XIST transcript plays a critical role in X-chromosome inactivation by physically coating one of the two X-chromosomes, and is necessary for the cis-inactivation of the over one thousand X-linked genes [75,108-110]. Like the IncRNAs HOTAIR and ANRIL, XIST associates with polycomb-repressor proteins, suggesting a common pathway of inducing silencing utilized by diverse IncRNAs. In mice, X inactivation in the extraembryonic tissues is non-random, and the initial expression of Xist is always paternal in origin, followed later by random X inactivation in the epiblast associated with random mono-allelic expression [111]. Intriguingly, regulation of Xist in mouse has been shown to be controlled by interactions amongst additional ncRNAs, including an antisense transcript, Tsix, enhancer-associated ncRNAs (Xite) and the upstream Jpx and Ftx IncRNAs [109,112-115]. Intriguingly, murine Xist and Tsix duplexes are processed into small RNAs by an apparently Dicer-dependent manner, suggesting a significant overlap between the regulatory networks of both IncRNAs and sRNAs [116]. It is unclear, however, how much of this regulation is conserved in humans, who do not show imprinted X inactivation [117]. While XIST expression levels are correlated with outcome in some cancers, such as the therapeutic response in ovarian cancer [118], the actual role that XIST may play in human carcinomas, if any, is not entirely clear.

There is generally believed to be only a limited developmental window in which X inactivation can occur, and loss of XIST from an inactive X chromosome does not result in reactivation of the X chromosome [119,120]. Thus, tumors with additional X chromosomes generally keep the inactivation status of the duplicated X. For tumors in which two active X chromosomes are observed, as has been frequently observed in breast cancer, the most common mechanism involves loss of the inactive X and duplication of the active X, often resulting in heterogeneous XIST expression in these tumors [121-123]. Loss of the inactive X and abnormalities of XIST expression may be indicative of more general heterochromatin defects [124]. Analogously, failure to properly reset XIST and X inactivation may serve as a marker of proper resetting of epigenetic marks in stem cells or induced pluripotent stem cells [125,126]. Correlations between XIST expression and cancer state can also occur spuriously. Notably, in cytogenetically normal cells, XIST is found only in females as males do not have an inactive X. Therefore in cancers correlations can be observed with XIST expression due to differential presence of male or female samples, and many cancers do show different onsets and progressions in males and females. Furthermore, XIST expression will increase with the number of inactive X chromosomes. While it might be anticipated that there would be little advantage to a tumor acquiring inactive chromosomes, it has been shown that approximately 15% of human X-linked genes continue to be expressed from the inactive X chromosome [127].

**Involvement in metastasis**

**HOTAIR - HOX antisense intergenic RNA** Several IncRNAs have been implicated in metastasis. One of the first IncRNAs described to have a fundamental role in cancer was the metastasis-associated HOX Antisense
Intergenic RNA (HOTAIR), a 2.2 kb gene located in the mammalian HOXC locus on chromosome 12q13.13 [18]. This IncRNA was found to be highly upregulated in both primary and metastatic breast tumors, demonstrating up to 2000-fold increased transcription over normal breast tissue [68]. High levels of HOTAIR expression were found to be correlated with both metastasis and poor survival rate, linking a ncRNA with cancer invasiveness and patient prognosis [68]. Furthermore, it was demonstrated that if cells expressing HOTAIR were grafted into mouse mammary fat pads, a modest increase in the rate of primary tumor growth was observed [68]. Interestingly, there are reports indicating that numerous lncRNAs are transcribed from the HOX locus, suggesting that HOTAIR may be only one example of a global regulatory phenomenon [58].

The spliced and polyadenylated HOTAIR RNA does not encode any proteins but has been demonstrated to be intimately associated with the mammalian polycomb repressive complex 2 (PRC2) which is comprised of the H3K27 methylase EZH2, SUZ12 and EED [68,128,129] (Figure 3). Polycomb group proteins mediate repression of transcription of thousands of genes controlling differentiation pathways during development, and have roles in stem cell pluripotency and human cancer [68,130-133].

HOTAIR binding results in a genome-wide re-targeting of the PRC2 complex. The HOXD locus on chromosome 2 is a PRC2 target (Figure 3). The consequence of PRC2/HOTAIR localization is the transcriptional silencing of a 40 kb region of the HOXD locus which remodels the gene expression pattern of breast epithelial cells to more closely resemble that of embryonic fibroblasts [68]. The HOTAIR RNA appears to act as a molecular scaffold, binding at least two distinct histone modification complexes. The 5' region of the RNA binds the PRC2 complex responsible for H3K27 methylation, while the 3' region of HOTAIR binds LSD1, a histone lysine demethylase that mediates enzymatic demethylation of H3K4Me2 [128,134]. Although, the precise mechanism of HOTAIR activities remains to be elucidated, it is clear that HOTAIR reprograms chromatin state to promote cancer metastasis.

MALAT1 - Metastasis-associated lung adenocarcinoma transcript 1 The MALAT1 gene, or metastasis-associated lung adenocarcinoma transcript 1, was first associated with high metastatic potential and poor patient prognosis during a comparative screen of non-small cell lung cancer patients with and without metastatic tumors [135]. This IncRNA is widely expressed in normal human tissues [135,136] and is found to be upregulated in a variety of human cancers of the breast, prostate, colon, liver and uterus [27,137-139]. Notably, the MALAT1 locus at 11q13.1 has been identified to harbor chromosomal translocation breakpoints associated with cancer [140-142].

Intriguingly, cellular MALAT1 transcripts are subject to post-transcriptional processing to yield a short, tRNA-like molecule mascRNA and a long MALAT1 transcript with a poly(A) tail-like moiety [143] (Figure 4). Using the mouse homologue to the human MALAT1 gene, it was
revealed that ribonuclease (RNase) P processing generates the 3’ end of the long MALAT1 transcript and the 5’ end of the mascRNA. The shorter mascRNA adopts a tRNA clover-leaf structure and is subject to RNaseZ processing and the addition of a CCA to its 3’ end before being exported to the cytoplasm. The generation of putatively functional sRNAs by post-transcriptional processing of IncRNAs, such as mascRNA from MALAT1, may be reflective of a central, unexplored theme in ncRNA biology [144]. Recent evidence suggests regulated post-transcriptional processing events, such as splicing and post-cleavage capping, may increase the functional diversity of the metazoan transcriptome [145-149]. In contrast, the long MALAT1 transcript is not polyadenylated, but has a poly(A) tail-like sequence that is genome encoded and is putatively present to protect the MALAT1 transcript from degradation. Moreover, MALAT1 localizes to nuclear speckles in a transcription dependent manner [136,150].

Following the correlation between high levels of MALAT1 expression and metastasis, a number of studies have implicated MALAT1 in the regulation of cell mobility. For example, RNA interference (RNAi)-mediated silencing of MALAT1 impaired the in vitro migration of lung adenocarcinoma cells through concomitant regulation of motility regulated genes via transcriptional and/or post-transcriptional means [151]. Similarly, short hairpin RNA inhibition of MALAT1 reduced cell proliferation and invasive potential of a cervical cancer cell line [152]. Collectively, these studies suggest that MALAT1 regulates the invasive potential of metastatic tumor cells. Other examples of cancer-associated IncRNAs subject to post-transcriptional processing include the miR-155 host gene BIC and the miR-17-92 cluster in B-cell lymphoma [156,157]. Each isoform contains the common exons 1-3 and 8-10, but varies in the combination of exons 4-7 in the middle of the transcript [158]. Notably, the last intron of MEG3 encodes the evolutionarily conserved miR-770, a miRNA with a number of putative mRNA targets [159]. This arrangement mirrors the presence of miR-675 in H19, except in that instance the miRNA was exon encoded [102]. The originally identified isoform of MEG3 is expressed as a 1.6 kb polyadenylated transcript that is localized to the nucleus where it is associated with chromatin although some cytoplasmic MEG3 transcripts have been detected [156,160,161]. All 12 MEG3 isoforms demonstrate three distinct secondary folding motifs designated M1, M2 and M3 [158].

Functionally, MEG3 has been implicated as a top-level regulatory RNA due to its ability to stimulate both p53-dependent and p53-independent pathways [158,162]. Critically, the MEG3-mediated functional activation of p53 is dependent on the secondary structure of the MEG3 RNA rather than on primary sequence conservation. In an elegant series of experiments, Zhang et al. demonstrated that replacing particular regions of the MEG3 with unrelated sequence had no effect on the activation of p53 provided the original secondary structure was preserved [158]. This observation strengthens the argument that the rapid evolution and relative lack of sequence conservation does not limit the potential functionality of these unique RNA species [163]. Conversely, the novel lincRNA-p21 has been described as a downstream repressor in the p53 transcriptional response, suggesting the complex p53 transcriptional network includes numerous regulatory IncRNAs [164].

Depletion of miRNAs by a lncRNA ‘molecular decoy’ or ‘miRNA sponge’

Expression of miRNAs in cancer can be deregulated by a range of mechanisms, including copy number alterations and epigenetic silencing [165-168]. Two recent
examples have demonstrated that lncRNAs can act as natural ‘miRNA sponges’ to reduce miRNA levels [169].

**HULC - Highly Upregulated in Liver Cancer** The most highly upregulated transcript found in a microarray-based study of gene expression in hepatocellular carcinoma was determined to be the ncRNA HULC, or Highly Upregulated in Liver Cancer [170]. Transcribed from chromosome 6p24.3, this lncRNA demonstrates the hallmarks of a typical mRNA molecule, including a single spliced GT-AG intron, canonical polyadenylation signals upstream of the poly(A) tail and nuclear export demonstrating strong localization to the cytoplasm. Although HULC was found to co-purify with ribosomes, no translation product for this lncRNA has been detected, supporting its classification as a non-coding transcript [170]. In addition to liver cancer, HULC was found to be highly upregulated in hepatic colorectal cancer metastasis and in hepatocellular carcinoma cell lines (HCC) producing hepatitis B virus (HBV) [171].

A recent paper began to elucidate the mechanism of upregulation of HULC in liver cancer cells, and to provide a potential mechanism of HULC function [172]. HULC exists as part of an intricate auto-regulatory network, which when perturbed, resulted in increased HULC expression (Figure 5). The HULC RNA appeared to function as a ‘molecular decoy’ or ‘miRNA sponge’ sequestering miR-372, of which one function is the translational repression of PRKACB, a kinase targeting cAMP response element binding protein (CREB). Once activated, the CREB protein was able to promote HULC transcription by maintaining an open chromatin structure at the HULC promoter resulting in increased HULC transcription [172].

**Pseudogene pairs: PTEN and PTENP1** The discovery that HULC can act as a molecular decoy or ‘miRNA sponge’ mirrors a recent report describing an intricate relationship between the tumor suppressor phosphatase and tensin homolog (PTEN) and the matching lncRNA phosphatase and tensin homolog pseudogene 1 (PTENP1) [173]. The RNA transcripts of the PTEN/PTENP1 pair share similar 3’ untranslated regions (3’UTRs) which both bind the same miRNAs. By binding miRNAs, PTENP1 transcripts reduce the effects of translational repression on PTEN therefore allowing expression of this tumor suppressor. In cancer, specific mutations inactivate these miRNA binding sites in PTENP1, therefore reducing the translation of PTEN and promoting tumor growth [173]. This is especially pertinent as subtle changes in PTEN levels can influence cancer susceptibility [174].

**LncRNA-mediated deregulation of the tumor suppressors**

**ANRIL - Antisense Non-coding RNA in the INK4 Locus** Located as part of the 42kb INK4b-ARF-INK4a locus on chromosome 9p21.3, the *Antisense Non-coding RNA in the INK4 Locus* (ANRIL) is transcribed by RNA pol II and processed into alternatively spliced isoforms, including an unspliced transcript of 34.8 kb termed p15AS [175,176]. The INK4b-ARF-INK4a locus has an important role in cell cycle control, cell senescence, stem cell renewal and apoptosis through P14ARF-MDM2-P53 and P16Ink4a/p15Ink4b-Cdk4/6-pRb pathways [177-179]. A mouse model suggests that the well-characterized tumor suppressor genes encoded within this locus are regulated by Polycomb proteins [180].

Ablation of expression and single nucleotide polymorphisms (SNPs) within ANRIL have been associated with susceptibility to a range of human diseases, including cancer [181,182]. Moreover, the INK4b-ARF-INK4a locus is subject to frequent deletion or hypermethylation in cancers, including leukemia, melanoma, lung and bladder cancers [181]. ANRIL has been associated with epigenetic silencing of the tumor suppressor gene *p15*, although the molecular events leading to this silencing were unclear [175].

Evidence has suggested an intriguing mechanisms for ANRIL-mediated silencing of the INK4b-ARF-INK4a locus. Recently an interaction between chromatin modifying PRC complexes and ANRIL has been described, further elucidating the regulatory mechanism of this lncRNA. Like the lncRNA HOTAIR which binds both the polycomb repressor complex PRC2 and the LSD1 complex, ANRIL binds and recruits two polycomb repressor complexes modifying complexes, PRC1 and PRC2 [183,184]. This resulted in ANRIL/PRC mediated silencing of the genes in the INK4b-ARF-INK4a locus. While the distinct regions of the HOTAIR lncRNA required for interactions with each protein complex were determined [128], future studies will be necessary to elucidate the structural requirements of lncRNAs.
such as ANRIL with chromatin regulators such as PRC1/PRC2.

The molecular details of ANRIL-mediated tumor suppression are becoming more clear. However, other mechanisms of IncRNA-mediated suppression of tumor suppressor genes have been reported. For example, a change in the expression ratio of bidirectional genes has been shown to mediate the expression of the tumor suppressor p21 [185]. Collectively, these observations suggest that IncRNA-mediated silencing of tumor suppressor genes may be a major mechanism driving tumorigenesis.

Cancer type specific IncRNA expression

Many of the described IncRNAs are expressed in a variety of cancers, however a select few thus far have been associated with a single cancer type. HOTAIR, for example, has only been described in breast cancer, while three IncRNAs PCGEM1, DD3 and PCNCR1 have been associated solely with prostate cancer [68,186,187]. The most recently described of these, Prostate Cancer Non-Coding RNA 1 (PCNCR1) IncRNA, was identified in a ‘gene desert’ on chromosome 8q24.2 and is associated with susceptibility to prostate cancer [187]. Likewise, PCGEM1 (Prostate Specific Gene 1) was found to have properties supporting tumorigenesis, as ectopic overexpression of PCGEM1 RNA resulted in increased cell growth and colony formation in cell lines [188]. The IncRNA Differential Display Code 3 (DD3) is also highly over expressed in prostate cancer, yet little is known about the role DD3 may play in prostate cancer progression [189,190]. Finally, the liver associated IncRNA HULC is highly expressed in primary liver tumors, and in colorectal carcinomas that metastasized to the liver, but not in the primary colon tumors or in non-liver metastases [171].

RNA polymerase III transcription of IncRNA

The IncRNAs described thus far are products of RNA pol II transcription, yet many ncRNAs are transcribed by RNA polymerase III (RNA pol III) [191]. Importantly, RNA pol III is frequently deregulated in cancer cells resulting in increased activity [192,193]. The molecular mechanisms driving increased RNA pol III activity in tumor cells include overexpression of RNA pol III transcription factors, escape from RNA pol III repressors and direct oncogene-mediated activation [193-195]. Aberrant RNA pol III function may have consequences to the expression of IncRNAs transcribed by this polymerase.

For example, the IncRNA BC200 is a small cytoplasmic IncRNA in the neurons of primate nervous systems and human cancers, but not in non-neuronal organs [20,50,51,196,197]. Unlike the majority of IncRNAs described thus far, BC200 is transcribed by RNA pol III and shares unique homology with human Alu elements [196,198]. Similarly, the IncRNA HULC also shares homology with mobile DNA, in this case with a long terminal repeat (LTR) retroelement [170]. The BC200 RNA has been characterized as a negative regulator of eIF4A-dependent translation initiation [199].

Due to the fact that many whole transcriptome sequencing methods were developed to enrich for poly(A) purified transcripts, RNA pol III transcripts may have been excluded from analysis. This suggests that other, yet unidentified RNA pol III IncRNAs over-expressed in cancer may be participating in tumorigenesis.

Aberrant T-UCR expression in human carcinoma

Transcribed ultraconserved Regions (T-UCRs) are evolutionary conserved sequences found in both intergenic and intragenic regions of the human genome [200,201]. These unique sequences are defined as 481 segments of DNA that are absolutely conserved between orthologous regions of the human, rat and mouse genomes [201,202]. The transcription products of T-UCRs are 200-779 nt in length and were originally classed into three categories, non-exonic, exonic and possibly exonic, according to their overlap with known protein-coding genes [202]. More recently, T-UCRs have been re-annotated into a more descriptive set of five categories: intergenic (38.7%), intronic (42.6%), exonic (4.2%), partly exonic (5%) or exonic containing (5.6%) (Figure 6) [59].

The high degree of conservation of T-UCRs, combined with their tissue-specific expression, suggests these ncRNAs may play a critical role in cellular metabolism and development [200]. The expression of many T-UCRs is significantly altered in cancer, notably in adult chronic lymphocytic leukemias, colorectal and hepatocellular carcinomas and neuroblastomas [85,200]. Their aberrant transcription profiles can be used to differentiate types of human cancers and have been linked to patient outcome [85]. Some of the T-UCRs reside in genomic regions associated with specific types of cancer [200]. For example, in colon cancer, the T-UCR uc.73A is one of the most highly
upregulated T-UCRs, and this lncRNA has been found to show oncogenic properties by proliferation assays [200]. Similarly, T-UCR uc.338 is significantly upregulated in human hepatocarcinoma tumor and cell lines, and uc.338 was found to be part of a larger transcriptional unit coined TUC338 which is involved in cell growth [203].

The mechanism by which T-UCRs are differentially expressed is unclear. A study profiling T-UCRs in neuroblastomas did not find a consistent association between genomic alterations and T-UCR expression, suggesting aberrant T-UCR expression may be a consequence of epigenetic mechanisms. Like miRNAs and coding genes, T-UCR expression has been shown to be repressed by CpG island hypermethylation [85,204]. Similarly, miRNAs have been shown to bind to, and downregulate T-UCRs, suggesting a complex regulatory mechanism may exist between ncRNAs in human cancers [85,200]. Collectively, these reports have suggested that aberrant T-UCR expression may have a yet undefined biological role in tumorigenesis.

Utility of LncRNAs in Cancer Diagnostics and Therapies
Like their smaller non-coding miRNA counterparts, LncRNAs represent a significant untapped resource in terms of developing diagnostics and therapies. Differential or high level expression of certain cancer type-specific LncRNAs can be exploited for the development of novel biomarkers as IncRNA expression or may potentially correlate with patient response to chemotherapy. Understanding the mechanism(s) by which LncRNAs act will continue to provide novel approaches to regulating genes including the development of mimetics to compete with binding sites for miRNAs, chromatin remodelers, or DNA.

It has been suggested that mediating transcriptional gene silencing (TGS) pathways, especially those of tumor suppressors or oncogenes, could be of high therapeutic benefit [205].

It has been widely reported that cancer-specific miRNAs are detectable in the blood, sputum and urine of cancer patients [206-210]. Likewise, LncRNAs have demonstrated utility as fluid-based markers of specific cancers. For example, the prostate specific LncRNA DD3 has been developed into highly specific, nucleic acid amplification-based marker of prostate cancer, which demonstrated higher specificity than serum prostate-specific antigen (PSA) [211,212]. Similarly, the highly expressed hepatocarcinoma-associated LncRNA HULC is detectable in the blood of hepatocarcinoma patients by conventional PCR methods [170].

The use of LncRNAs as therapeutic agents is only beginning to be explored [213]. Although our understanding of the molecular mechanisms of LncRNA function is limited, some features of LncRNAs make them ideal candidates for therapeutic intervention. Many LncRNAs appear to have protein-binding or functional potential that is dependent on secondary structure, this may provide a means of intervention [214]. Preventing the interactions of HOTAIR with the PRC2 or LSD1 complexes, for example, may limit the metastatic potential of breast cancer cells [215].

The tumor expression of certain LncRNAs provides a source of regulatory regions that can be used to reduce the risk of affecting normal tissues during transgene-mediated treatment. For example, H19 is strongly expressed in embryonic cells and in a wide-range of human cancers [20,93,94]. As such, a plasmid-based system has been developed to exploit the tumor-specific expression of H19, primarily tested in treating bladder cancer. A plasmid construct, harboring a diptheria toxin gene driven by H19 specific regulatory sequences, is either administered via intratumoral injection as naked DNA, or complexed to the cationic polymer polyethylenimine (PEI) to form a polyplex vector [216]. PEI-complexed plasmid is thought to increase the efficiency of DNA uptake via clathrin-dependent and -independent (cholesterol-dependent) pathways [217]. Upon uptake, high levels of diptheria toxin are expressed in the tumor, resulting in a reduction in tumor size in human trials [218-221]. Collectively, these advances indicate the potential in developing LncRNA mediated diagnostics and therapies.

Conclusions
Differential expression of LncRNAs is becoming recognized as a hallmark feature in cancer, however the functional role for the vast majority of these unique genes is still in question. In this review, we highlight characterized LncRNAs described to play a functional role in cancer-associated processes, such as metastasis and loss of imprinting. Aberrant LncRNA expression participates in carcinogenesis by disrupting major biological processes, such as redirecting chromatin remodeling complexes or inactivating major tumor suppressor genes. We also describe the potential role of dysregulated T-UCRs in cancer, and place these unique RNAs in the LncRNA category. Finally, we note the potential utility of LncRNAs in cancer as diagnostic and prognostic markers, as well as the potential of developing LncRNA mediated therapy.

Abbreviations
ANRIL: Antisense Non-coding RNA in the INK4 Locus; AR: androgen receptor; CREB: cAMP response element binding protein; DD3: Differential Display Code 3; HBV: hepatitis B virus; HCC: hepatocellular carcinoma cell lines; HOTAIR: Hox Antisense Intergenic RNA; HULC: Highly Upregulated in Liver Cancer; IGF2: Insulin-Like Growth Factor 2; kb: kilobase; lncRNA: long or large intergenic non-coding RNA; LTR: long terminal repeat; MALAT1: Metastasis-Associated Lung Adenocarcinoma Transcript 1; MEG3: Maternally Expressed Gene 3; miRNA: microRNA; nRNA: non-coding RNA; nt: nucleotide; PCCR: Prostate Cancer Non-Coding RNA 1; PEI: polyethylenimine; PRC: polycomb repressive complex; PTEV:
phosphatase and tensin homolog, PTENP1: phosphatase and tensin homolog pseudogene 1; RNase: ribonuclease; RNA pol II: RNA polymerase II; RNA pol III: RNA polymerase III; RNAi: RNA interference; SR: serine-arginine rich splicing proteins; TGS: transcriptional gene silencing; tRNA: transcription initiation tRNAs; T-JURC: transcribed ultraconserved region; UTR: untranslated region; XIST: X-Inactive-Specific Transcript.

Acknowledgements

We would like to thank Chad Malloff and Gavin Wilson for their insightful comments. This work was supported by funds from the Canadian Institutes for Health Research (MOP 96731, MOP 77903 to WLL and MOP 13690 to CJB), Canadian Cancer Society (CCS20485), NCI Early Detection Research Network (SU01 CA84977-10) and Department of Defense (CDMRP W81XWH-10-1-0634).

Author details

1. British Columbia Cancer Agency Research Centre, Vancouver, Canada.
2. Department of Medical Genetics, University of British Columbia, Vancouver, Canada.
3. Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada.

Authors’ contributions

EAGs wrote the first draft of the article, CJB and WLL finalized the manuscript. All authors read and approved the final manuscript.

Authors’ information

EAG is a research fellow at the BC Cancer Agency Research Centre, specializing in non-coding RNA gene structure and function. CJB is a professor of Medical Genetics at the University of British Columbia. Her research focuses on human X chromosome inactivation, in particular the role of XIST, a gene she first described during postdoctoral studies in the Willard lab. WLL is a professor of Pathology and Laboratory Medicine at the University of British Columbia. His team invented tiling path array technologies for whole genome and methylome analyses.

Competing interests

The authors declare that they have no competing interests.

Received: 13 January 2011 Accepted: 13 April 2011
Published: 13 April 2011

References

1. Stein LD: Human genome: end of the beginning. Nature 2004, 431(7011):915-916.
2. Ponting CP, Belagd TG: Transcribed dark matter: meaning or myth? Hum Mol Genet 2010, 19(9):R162-168.
3. Birney E, Stamatoyannopoulos JA, Dutta A, Guigo R, Gingeras TR, et al: Identification and analysis of functional elements in 1% of the human genome from the ENCODE pilot project. Nature 2007, 447(7146):799-816.
4. Costa FF: Non-coding RNAs: Meet thy masters. Bioessays 2010, 32(7):599-608.
5. Kapranov P, Willingham AT, Gingeras TR: Genome-wide transcription and the implications for genomic organization. Nat Rev Genet 2007, 8(6):413-423.
6. Freth MC, Pheasant M, Mattick JS: The amazing complexity of the human transcriptome. Eur J Hum Genet 2005, 13(8):894-897.
7. Khatrani AN, Harrison PM: Mining mammalian transcript data for functional long non-coding RNAs. PLoS One 2010, 5(4):e10316.
8. Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D, Huarte M, Zuk O, Carey BW, Cassidy JF, et al: Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 2009, 458(7235):223-227.
9. Mattick JS, Makunin I: Non-coding RNA. Hum Mol Genet 2006, 15(1):R17-29.
10. Washietl S, Hofacker IL, Lukasser M, Hutterer A, Stadler PF: Mapping of conserved RNA secondary structures predicts thousands of functional long non-coding RNAs in the human genome. Nat Biotechnol 2005, 23(11):1383-1390.
11. Wang J, Zhang J, Zheng H, Li J, Liu D, Li H, Samudrala R, Yu J, Wong GK: Mouse transcriptome: neutral evolution of ‘non-coding’ complementary DNAs. Nature 2004, 431(7010):1, p following 757; discussion following 757.
39. Taft Rj, Glazov EA, Cloonan N, Simors C, Stephen S, Faulkner GJ, Lassmann T, Forrest AR, Grimm SM, Schroder K, et al. Tiny RNAs associated with transcription start site in animals. Nat Genet 2009, 41(5):572-578.
40. Taft Rj, Simors C, Nahhari S, Oey H, Korbie DJ, Mercer TR, Holst J, Ritchie W, Wong Jt, Rasko JE, et al. Nuclear-localized tiny RNAs are associated with transcription initiation and splice sites in metazoans. Nat Struct Mol Biol 2010, 17(8):1030-1034.
41. Farazi TA, Spitzer J, Morozov P, Tuschl T. miRNAs in human cancer. J Pathol 2011, 223(2):102-115.
42. Fabbri M, Calin GA. Epigenetics and miRNAs in human cancer. Adv Genet 2010, 70:87-99.
43. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol 2009, 27(34):5848-5856.
44. Chang LS, Lin SY, Lieu AS, Wu TL: Poly A- transcripts expressed in HeLa cells. Proc Natl Acad Sci USA 2010, 107(1):57-62.
45. Cheng J, Kapranov P, Drenkow J, Dike S, Brubaker S, Patel S, Long J, Stern D, Tammana H, Helt G, et al. Transcriptional maps of 10 human chromosomes at 5-nucleotide resolution. Science 2005, 308(5725):1149-1154.
46. Wu Q, Kim YC, Lu J, Xuan Z, Chen J, Zheng Y, Zhou T, Zhang MQ, Wu CI, Wang SM: Poly A- transcripts expressed in HeLa cells. Proc Natl Acad Sci USA 2010, 107(1):57-62.
47. Guttman M, Garber M, Levin JZ, Donaghey J, Robinson J, Adiconis X, et al. An integrated genomic screen uncovers ncRNA T-UCR functions in neuroblastoma tumors. Oncogene 2010, 29(24):3583-3592.
48. Orom UA, Derenit T, Beringer M, Gumireddy K, Gardini A, Bussotti G, Lai F, Zylinski M, Notredame C, Huang Q, et al. Long noncoding RNAs with enhancer-like function in human cells. Cell 2010, 141(1):46-58.
49. Chen LL, Carmichael GG: Decoding the function of nuclear long non-coding RNAs. Curr Opin Cell Biol 2010, 22(3):357-364.
50. Lipovich L, Johnson R, Lin CY: MacroRNA underdogs in a microRNA world: evolutionary, regulatory, and biomedical significance of mammalian long non-protein-coding RNA. Biochim Biophys Acta 2010, 1799(9):597-615.
51. Costa FF: Non-coding RNAs, epigenetics and complexity. Gene 2008, 410(1):19-70.
52. Yang PK, Kuroda MI: Noncoding RNAs and intranuclear positioning in monoallelic gene expression. Cell 2007, 128(4):777-786.
53. Liu J, Yang L, Duff MO, Graveley BR, Carmichael GG, Chen LL: The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell 2010, 39(6):925-938.
54. Goodrich JA, Kugel JF: Non-coding RNA regulators of RNA polymerase II transcription. Nat Rev Mol Cell Biol 2006, 7(9):612-616.
55. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, TsaI MC, Hung T, Argani P, Rinn JL, et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464(7291):1071-1076.
56. Franash IV, Spector DI: Eukaryotic regulatory RNAs: an answer to the 'genome complexity' conundrum. Genes Dev 2007, 21(11):11-42.
57. Gong C, Maquat LE: IncRNAs transactivate STAUI-mediated mRNA decay by duplexing with 3' UTRs via Alu elements. Nature 2011, 470(7333):284-288.
58. Huarte M, Rinn JL: Large non-coding RNAs: missing links in cancer? Mol Med 2010, 16(2):152-161.
59. Kondo T, Plaza S, Zanet J, Benrabah E, Valenti P, Hashimoto Y, Kobayashi Y, Payne F, Kagayama Y: Small peptides switch the transcriptional activity of Shavenbaby during Drosophila embryogenesis. Science 2010, 329(5989):336-339.
60. Urvieilleg D, Franscati C, Hube F: When one is better than two: RNA with dual functions. Biochimie 2010.
61. Babak T, Blencowe BJ, Hughes TR: Many human noncoding RNAs indicate little conserved intergenic sequence data. Adv Genet 2010, 63:39-66.
62. Costa FF. Long non-coding RNAs with enhancer-like function in human cells. Cell 2010, 141(1):46-58.
...
137. Yamada K, Kano J, Tsunoda H, Yoshikawa H, Okubo C, Ishiyama T, Noguchi M: Phenotypic characterization of endometrial stromal sarcoma of the uterus. Cancer Sci 2006, 97(1):110-112.

138. Lin R, Maeda S, Liu C, Karl M, Edgington TS: A large noncoding RNA is a marker for murine hepatocellular carcinomas and a spectrum of human carcinomas. Oncogene 2007, 26(5):851-858.

139. Luo JH, Ren B, Keryanov S, Tseng GC, Rao UN, Monga SP, Strom S, Kuiper RP, Schepens M, Thijssen J, van Asseldonk M, van den Berg E, Bridge J, Noguchi M: Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad Sci USA 2010, 107(21):11161-11166.

140. Lin R, Maeda S, Liu C, Karin M, Edgington TS: Identification of new RNA classes and a possible function for pervasive transcription. Science 2007, 316(5830):1484-1488.

141. Pang KC, Frith MC, Mattick JS: Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet 2006, 22(1):1-5.

142. Kaminski N, Lacombe F, Demetris AJ, Nalesnik M, Yu YP, et al: Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatology 2006, 44(4):1012-1020.

143. Davis JJ, Hsi BL, Anway JD, Vargas SQ, Yeh YA, Motykova G, Valencia P, Perez-Atayde AR, Argani P, Ladanyi M, et al: Cloning of an Alpha-TFE fusion in two primary renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci USA 2003, 100(10):6051-6056.

144. Kapranov P, Cheng J, Dike S, Nix DA, Duttagupta R, Willingham AT, Antonellis P, von Stedingk K, Ghersu M, Dev M, et al: RNA maps reveal new RNA classes and a possible function for pervasive transcription. Nat Methods 2007, 4(9):765-773.

145. Tano K, Mizuno R, Okada T, Rakwal R, Shibato J, Masuo Y, Ijiri K, Akimitsu N: miR-17-92 microRNA cluster regulates multiple components of the TGF-beta signaling pathway in neuroblastoma. Mol Cell 2010, 40(5):762-773.

146. Zhang MQ, Sedel F, Jourdren L, Coulpier F, Zhang Z, Bendtsen JN, Steen H, et al: Elongation factor TFEB in t(6;11)(p21;q13)-positive renal cell carcinomas. Hum Mol Genet 2010, 19(17):3509-3517.

147. Zhang X, Zhou Y, Mehta KR, Danila DC, Scolavino S, Johnson SR, Ribinski A: A pituitary-derived MEG3 isomiR functions as a growth suppressor in tumor cells. J Clin Endocrinol Metab 2008, 93(11):5119-5126.

148. Zhang X, Rice K, Wang Y, Chen W, Zhong Y, Nakayama Y, Zhou Y, Ribinski A: Maternally expressed gene 3 (MEG3) noncoding ribonucleic acid: isomiR structure, expression, and functions. Endocrinology 2010, 151(9):939-947.

149. Hagan JP, O’Neill BL, Stewart CL, Kozlov SV, Croce CM: At least ten genes define the imprinted Dlk1-Dio3 cluster on mouse chromosome 12Fq1. PLoS One 2009, 4(2):e3932.

150. Bernard D, Prasanth KV, Tripathi V, Colasse S, Nakamura T, Xuan Z, Wu X, Shen L, Juge N, et al: Rapid evolution of noncoding RNAs: lack of conservation does not mean lack of function. Trends Genet 2006, 22(1):1-5.
177. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1999, 366(6456):704-707.

178. Kamb A, Grun NA, Weaver-Feldhaus J, Liu Q, Hamshani K, Tavignant SV, Stockert E, Day RS, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994, 264(5175):436-440.

179. Kamijo T, Zindy F, Roussel MF, Quelle DE, Downing JR, Ashmun RA, Kamb A, Gruis NA, Weaver-Feldhaus J, Liu Q, Harshman K, Tavtigian SV, Serrano M, Hannon GJ: Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. Cell 1997, 91(5):649-659.

180. Jacobs J, Kebooom K, Marino S, DePinho RA, van Lohuizen M: The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 1999, 397(6715):164-168.

181. Popov N, Gil J: Epigenetic regulation of the INK4b-ARF-INK4a locus: in sickness and in health. Epigenetics 2010, 5(8):685-690.

182. Cunningham MS, Santibanez Koref M, Mayosi BM, Bum J, Kneaven B: Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ARNIR Expression. PloS Genet 2010, 6(4):e1000899.

183. Yap KL, Li S, Munoz-Cabello A, Zeng L, Mujtaba S, Gil J: Non-coding RNA in 8q24 with prostate cancer susceptibility. Proc Natl Acad Sci USA 2010, 107(18):8027-8032.

184. Kokke JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Szell M, Bata-Csorgo Z, Kemeny L: Transcriptional silencing of INK4a. Mol Cell 2008, 31(5):662-674.

185. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M, Xiong Y: Long non-coding RNA ANRIL is required for the PR2C recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 2010.

186. Tiedge H, Chen W, Brosius J, Patel T: Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA 2010.

187. Cimmino A, Lee EJ, Wojcik SE, Alatas M, Deepak J, Stass SA, Jiang F: Alternative miRNA expression in sputum for diagnosis of non-small cell lung cancer. Lung Cancer 2010, 67(2):170-176.

188. Lujambio A, Portela A, Ruiz M, Melo SA, Rossi S, Spizzo R, Croce CM, Esteller M: Epigenetic dysregulation of the INK4a-P16INK4a gene cluster in human cancers. Nat Rev Cancer 2010, 10(1):39-51.

189. Paull TT, Henson JW, Tucker SL, Johnson BE, Skolnick MH: A cell cycle regulator potentially involved in genesis of many tumor types. J Clin Oncol 2007, 25(35):5272-5278.

190. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Mancini A, Lee EJ, Woychik SE et al: Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007, 12(3):215-229.

191. Agarwal S, Seshasayee A, Pletnev J, Fialkow PJ: Coregulation of ANRIL expression and Methylation of the INK4A/ARF Locus. Cancer Res 2008, 68(18):7265-7272.

192. Sakurai T, Sato T, Itoh T, Noguchi T, Muto T, Chiba T, Fujiwara M, Yoshioka H, Ichimura K, Nakanishi T et al: A novel long non-coding RNA downstream of the H19 gene in DNA based therapy of bladder cancer. Exp Hematol 2010, 38(7):915-919.

193. Tuszynski GP, Tamayoa C, Hahnel DJ, Smaldone MC, Davies BJ: Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007, 12(3):215-229.

194. Tuszynski GP, Tamayoa C, Hahnel DJ, Smaldone MC, Davies BJ: Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007, 12(3):215-229.

195. Negrini M, Reventos J, Auwerx J: The role of lncRNAs and miRNAs in cancer. Nat Rev Cancer 2009, 9(12):887-897.

196. Kalisky T, Segal E: Expression of long non-coding RNAs in human cancers. Trends Genet 2009, 25(10):434-441.

197. Tiedge H, Chen W, Brosius J, Patel T: Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA 2010.

198. Serrano M, Hannon GJ, Beach D: A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1999, 366(6456):704-707.

199. Wainscoat JS, Hodge KK, Petricoin EF,有毒 RNA与癌细胞的相关性研究。J Transl Med 2009, 7(1):85.

200. Calin GA, Liu CG, Ferracin M, Hyslop T, Spizzo R, Sevignani C, Fabbri M, Mancini A, Lee EJ, Woychik SE et al: Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell 2007, 12(3):215-229.
222. Pihaczky EM, Hopper AK: tRNA biology charges to the front. Genes Dev 2010, 24(17):1832-1860.
223. Hannan KM, Hannan RD, Rothblum Li: Transcription by RNA polymerase I. Front Biosci 1998, 3:376-398.
224. Stultz DM, Killen MW, Pierce HHI, Pierce AJ: Genomic architecture and inheritance of human ribosomal RNA gene clusters. Genome Res 2008, 18(1):13-18.
225. Lin H: piRNAs in the germ line. Science 2007, 316(5823):397.
226. Kapranov P, Ozsolak F, Kim SW, Foisip S, Lindsay D, Hart C, Roels S, Borel C, Antonarakis SE, Monaghan AP, et al: New class of gene-termi-associated human RNAs suggests a novel RNA copying mechanism. Nature 2010, 466(7300):642-646.
227. Kiss T: Small nuclear RNA-guided post-transcriptional modification of cellular RNAs. EMBO J 2001, 20(14):3617-3622.
228. Filipowicz W, Pogacic V: Biogenesis of small nuclear ribonucleoproteins. Curr Opin Cell Biol 2002, 14(3):319-329.
229. Sela AC, Galabrese JM, Levine SS, Yeo GW, Rahl PB, Flynn RA, Young RA, Sharp PA: Divergent transcription from active promoters. Science 2008, 322(5909):1849-1851.
230. Valadihan S: snRNAs as the catalysts of pre-mRNA splicing. Curr Opin Chem Biol 2005, 9(6):603-608.
231. Faulkner GJ, Carninci P: Attribural functions for selfish RNA. Cell Cycle 2009, 8(18):3899-3909.
232. Faulkner GJ, Kimura Y, Daub CO, Waltz S, Plessy C, Irvine KM, Schroder K, Valadkhan S: Human and mouse transcriptome of mammalian cells. Genome Res 2009, 19(12):2172-2179.
233. Kandhavelu M, Lammi C, Buccioni M, Dal Ben D, Volpini R, Marucci G: Integrative genomic analysis of unitary pseudogenes: historic and contemporary gene losses in the human transcriptome. Genome Res 2009, 19(12):2168-2171.
234. Phizicky EM, Hopper AK: The Functional RNA Database 3.0: databases to support functional RNA biology. Nucleic Acids Res 2010, 38(Database issue):D162-164.
235. Mitsuyama T, Yamada K, Haritani E, Okida H, Ono Y, Tarai G, Yoshizawa A, Komori T, Aisaka K: The Functional RNA Database 3.0: databases to support mining and annotation of functional RNAs. Nucleic Acids Res 2009, 37(Database issue):D89-92.
236. Lu C, Bai B, Skogerbog C, Gai L, Deng W, Zhang Y, Bu D, Zhao Y, Chen R: NONCODE: an integrated knowledge database of non-coding RNAs. Nucleic Acids Res 2005, 33(Database issue):D121-125.
237. Armaral PP, Clark MB, Gascoigne DK, Dinger ME, Mattick JS: IndRnaDB: a reference database for long non-coding RNAs. Nucleic Acids Res 2011, 39(Database issue):D146-151.
238. Gardner PP, Daub J, Tate JG, Navrocki EP, Kolbe DL, Lindgreen S, Wilkinson AC, Finn RD, Griffiths-Jones S, Eddy SR, et al: Rfam: updates to the RNA families database. Nucleic Acids Res 2009, 37(Database issue):D70-75.
239. Zheng R, Shen Z, Tripathi V, Xuan Z, Freier SM, Bennett CF, Prasanth SG, Rearick D, Prakash A, McSweeny A, Shepard SS, Fedorova L, Fedorov A: NPInter: the noncoding RNAs and protein related biomacromolecules interaction database. Nucleic Acids Res 2006, 34(Database issue):D150-152.
240. Fellenberg J, Bernd L, Delling G, Witte D, Zalzhen-Hungerman A: Altruistic functions for selfish DNA. Curr Opin Cell Biol 2007, 19(1):642-646.
241. Zheng D, Frankish A, Mercer TR, Crowe NL, Grimmond SM, Mattick JS: NRED: a database of long noncoding RNA expression. Nucleic Acids Res 2009, 37(Database issue):D122-126.
242. Erdmann VA, Szymanski M, Hochberg A, Groat N, Barciszewski J: Non-coding, mRNA-like RNAs database Y2K. Nucleic Acids Res 2000, 28(1):197-200.
243. Wuj T, Wang J, Liu C, Zhang Y, Shi B, Zhu X, Zhang Z, Skogerbog C, Chen L, Lu H, et al: NPInter: the noncoding RNAs and protein related biomacromolecules interaction database. Nucleic Acids Res 2006, 34(Database issue):D150-152.
244. Li Z, Kim SW, Lin Y, Moore PS, Chang Y, John B: Characterization of viral and human RNAs smaller than canonical MicroRNAs. PLoS Comput Biol 2007, 3(12):2895-2900.
245. Gehrig M, Hauffe P, Graßl K, Alecu P, Richter MC, Söllner M, et al: Human PCGEM1, a novel antisense gene, is overexpressed in prostate cancer. Oncogene 2009, 28(12):1607-1612.
246. Szymanski M, Erdmann VA, Barciszewski J: Non-coding RNAs database (ncRNaDB). Nucleic Acids Res 2007, 35(Database issue):D162-164.
247. Hayashi K, Yamada K, Haritani E, Okida H, Ono Y, Tarai G, Yoshizawa A, Komori T, Aisaka K: The Functional RNA Database 3.0: databases to support mining and annotation of functional RNAs. Nucleic Acids Res 2009, 37(Database issue):D89-92.
248. Liu C, Bai B, Skogerbog C, Gai L, Deng W, Zhang Y, Bu D, Zhao Y, Chen R: NONCODE: an integrated knowledge database of non-coding RNAs. Nucleic Acids Res 2005, 33(Database issue):D121-125.
249. Novokmet A, Malkin D: Recurrent focal copy-number changes and loss of heterozygosity implicate two noncoding RNAs and one tumor suppressor gene in human lung cancer. J Clin Oncol 2004, 22(18):3606-3613.
268. Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW, Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, et al: Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res 2006, 12(16):4851-4858.

269. Wang F, Li X, Xie X, Zhao L, Chen W: UCA1, a non-protein-coding RNA up-regulated in bladder carcinoma and embryo, influencing cell growth and promoting invasion. FEBS Lett 2008, 582(13):1919-1927.

270. Tsang WP, Wong TW, Cheung AH, Co CN, Kwok TT: Induction of drug resistance and transformation in human cancer cells by the noncoding RNA CUDR. RNA 2007, 13(6):890-898.

271. Korneev SA, Korneeva EI, Lagarkova MA, Kiselev SI, Critchley G, O'Shea M: Novel noncoding antisense RNA transcribed from human anti-NOS2A locus is differentially regulated during neuronal differentiation of embryonic stem cells. RNA 2008, 14(10):2030-2037.

272. Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I: Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression colocalizes with ARF. Cancer Res 2007, 67(8):3963-3969.

273. Mourtada-Maarabouni M, Pickard MR, Hedge VL, Farzaneh F, Williams GT: GASS, a non-protein-coding RNA, controls apoptosis and is downregulated in breast cancer. Oncogene 2009, 28(21):195-208.

274. Leygue E: Steroid receptor RNA activator (SRA1): unusual bifaceted gene products with suspected relevance to breast cancer. Nucl Recept Signal 2007, 5:e006.

275. Chooniedass-Kothari S, Hamedani MK, Troup S, Hube F, Leygue E: The steroid receptor RNA activator protein is expressed in breast tumor tissues. Int J Cancer 2006, 118(4):1054-1059.

276. Zhu Y, Yu M, Li Y, Nizuma H, Oo ML, Zhu Y, Ozaki T, Isogai E, Nakamura Y, Kodá T, et al: High expression of ncRAN, a novel non-coding RNA mapped to chromosome 17q25.1, is associated with poor prognosis in neuroblastoma. Int J Oncol 2009, 34(4):931-938.

doi:10.1186/1476-4598-10-38
Cite this article as: Gibb et al.: The functional role of long non-coding RNA in human carcinomas. Molecular Cancer 2011 10:38.